Departments of Pediatrics and Immunology, Duke University Medical Center, Box 2898 or 363 Jones Building, Durham, NC 27710, USA.
Immunol Res. 2011 Apr;49(1-3):25-43. doi: 10.1007/s12026-010-8191-9.
Severe combined immunodeficiency (SCID) is a syndrome of diverse genetic cause characterized by profound deficiencies of T- and B-cell function and, in some types, also of NK cells and function. Mutations in thirteen different genes have been found to cause this condition, which is uniformly fatal in the first 2 years of life unless immune reconstitution can be accomplished. In the 42 years since the first bone marrow transplant was given in 1968, the standard treatment for all forms of SCID has been allogeneic bone marrow transplantation. Both HLA-identical unfractionated and T-cell-depleted HLA-haploidentical bone marrow transplants have been very successful in effecting immune reconstitution, especially if performed in the first 3.5 months of life and without pre-transplant chemotherapy. This paper summarizes the longterm outcome, according to molecular type, of 166 consecutive SCID infants given non-conditioned related donor bone marrow transplants at this institution over the past 28.3 years and reviews published reports of longterm outcomes of transplants in SCID performed at other centers.
严重联合免疫缺陷症(SCID)是一种由多种遗传原因引起的综合征,其特征是 T 细胞和 B 细胞功能严重缺陷,在某些类型中,NK 细胞和功能也会受到影响。已经发现十三个不同的基因发生突变会导致这种情况,如果不能进行免疫重建,这种情况在生命的头 2 年内是致命的。自 1968 年首次进行骨髓移植以来,42 年来,所有类型的 SCID 的标准治疗方法都是同种异体骨髓移植。非 HLA 配型未分选出的和 T 细胞耗竭的 HLA 半相合骨髓移植在实现免疫重建方面都非常成功,尤其是在生命的头 3.5 个月内进行,且无需移植前化疗。本文总结了过去 28.3 年来,本机构对 166 例连续 SCID 婴儿进行非条件相关供体骨髓移植的长期结果,根据分子类型进行了分类,并回顾了其他中心进行的 SCID 移植的长期结果报告。